Felix Alexander Böhm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felix Alexander Böhm has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Angela Casini
Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich, Lichtenbergstr. 4, D-85748 Garching b. München, Germany
4 shared publications - Guillermo Moreno-Alcántar
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
2 shared publications - Mihyun Park
Technical University of Munich
2 shared publications - Alessandro Marrone
Department of Pharmacy, University “G. D'Annunzio” of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
1 shared publication Ana Luiza de Andrade Querino
Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Lichtenbergstraße 4, 85748 Garching bei München, Germany
1 shared publication- Bernd Schulz
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4957-4966
Bioactivity studies of organometallic Cp*Rh( iii ) and Au( i ) NHC complexes bioconjugated to integrin binding peptides
Au( i ) and Rh( iii ) cRGD peptide-conjugates were developed for cancer targeting. Experiments and DFT models showed that metal integration uniquely impacts integrin binding and cellular uptake, guiding future targeted metallodrug design.
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4957-4966
Open AccessBioactivity studies of organometallic Cp*Rh( iii ) and Au( i ) NHC complexes bioconjugated to integrin binding peptides
Au( i ) and Rh( iii ) cRGD peptide-conjugates were developed for cancer targeting. Experiments and DFT models showed that metal integration uniquely impacts integrin binding and cellular uptake, guiding future targeted metallodrug design.
- Open Access
- 13 April 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (21) , 10504-10510
A photocleavable peptidic Ru( ii ) mass-tag enabling targeted DESI and MALDI mass spectrometry imaging in cancer tissues
Mass-tag with photocleavable Ru( ii ) complex and peptidic binding motif enables bimodal SSTR2 imaging via MALDI- and DESI-MSI, compatible with commercial antibody-based mass-tags for multiplex imaging of disease-relevant proteins in tissue.
- 13 April 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (21) , 10504-10510
Open AccessA photocleavable peptidic Ru( ii ) mass-tag enabling targeted DESI and MALDI mass spectrometry imaging in cancer tissues
Mass-tag with photocleavable Ru( ii ) complex and peptidic binding motif enables bimodal SSTR2 imaging via MALDI- and DESI-MSI, compatible with commercial antibody-based mass-tags for multiplex imaging of disease-relevant proteins in tissue.
- Open Access
- 6 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Post-assembly modification of Pt(II) metallacages: an open door to medicinal applications
Metallacages (MCgs) have emerged as highly tunable modular – multicomponent and multifunctional – platforms with promising applications in catalysis, sensing, and medicine. Strategies for the synthesis of MCgs have been developed over the last decades, supplying several remarkable structures with striking varieties of size, shapes, and functions. Yet the efficient formation of systems with increased complexity and functionality remains a significant challenge towards their translation into practice. In particular, the transition of MCgs to medicine as next generation ‘theranostic’ agents requires not only the generation of robust structures, but also the development of tailored strategies towards the integration of different bioactive components. In this context, this work presents a general workflow for the facile microwave-assisted synthesis of kinetically inert platinum(II)-MCgs and their post-assembly modification (PAM) via amide coupling and copper-catalyzed click chemistry. This approach enables the incorporation of diverse functional groups under mild conditions, including a fluorescent rhodamine label for optical imaging, a targeting cyclo(RGDfK) peptide, and a DOTA-derived chelator for complexation of radioactive isotopes, demonstrating the versatility and compatibility of the method with biologically relevant functionalities. Overall, our work expands the synthetic accessibility and functional scope of Pt(II)-MCgs, paving the way to their application in drug delivery, imaging, supramolecular radiotheranostics, and beyond.
- 6 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPost-assembly modification of Pt(II) metallacages: an open door to medicinal applications
Metallacages (MCgs) have emerged as highly tunable modular – multicomponent and multifunctional – platforms with promising applications in catalysis, sensing, and medicine. Strategies for the synthesis of MCgs have been developed over the last decades, supplying several remarkable structures with striking varieties of size, shapes, and functions. Yet the efficient formation of systems with increased complexity and functionality remains a significant challenge towards their translation into practice. In particular, the transition of MCgs to medicine as next generation ‘theranostic’ agents requires not only the generation of robust structures, but also the development of tailored strategies towards the integration of different bioactive components. In this context, this work presents a general workflow for the facile microwave-assisted synthesis of kinetically inert platinum(II)-MCgs and their post-assembly modification (PAM) via amide coupling and copper-catalyzed click chemistry. This approach enables the incorporation of diverse functional groups under mild conditions, including a fluorescent rhodamine label for optical imaging, a targeting cyclo(RGDfK) peptide, and a DOTA-derived chelator for complexation of radioactive isotopes, demonstrating the versatility and compatibility of the method with biologically relevant functionalities. Overall, our work expands the synthetic accessibility and functional scope of Pt(II)-MCgs, paving the way to their application in drug delivery, imaging, supramolecular radiotheranostics, and beyond.
- Open Access
- 13 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17516-17526
N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design
The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β– particles suitable for effective cancer radiotherapy, making it a perfect nuclide for “theranostics”. However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood–brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
- 13 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17516-17526
Open AccessN-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design
The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β– particles suitable for effective cancer radiotherapy, making it a perfect nuclide for “theranostics”. However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood–brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.